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Abstract
Background: Agonistic autoantibodies to the a1-adrenergic receptor occur in nearly half of patients with refractory
hypertension; however, their relevance is uncertain.
Methods/Principal Findings: We immunized Lewis rats with the second extracellular-loop peptides of the human a1A-
adrenergic receptor and maintained them for one year. a1A-adrenergic antibodies (a1A-AR-AB) were monitored with a
neonatal cardiomyocyte contraction assay by ELISA, and by ERK1/2 phosphorylation in human a1A-adrenergic receptor
transfected Chinese hamster ovary cells. The rats were followed with radiotelemetric blood pressure measurements and
echocardiography. At 12 months, the left ventricles of immunized rats had greater wall thickness than control rats. The
fractional shortening and dp/dtmax demonstrated preserved systolic function. A decreased E/A ratio in immunized rats
indicated a diastolic dysfunction. Invasive hemodynamics revealed increased left ventricular end-diastolic pressures and
decreased dp/dtmin. Mean diameter of cardiomyocytes showed hypertrophy in immunized rats. Long-term blood pressure
values and heart rates were not different. Genes encoding sarcomeric proteins, collagens, extracellular matrix proteins,
calcium regulating proteins, and proteins of energy metabolism in immunized rat hearts were upregulated, compared to
controls. Furthermore, fibrosis was present in immunized hearts, but not in control hearts. A subset of immunized and
control rats was infused with angiotensin (Ang) II. The stressor raised blood pressure to a greater degree and led to more
cardiac fibrosis in immunized, than in control rats.
Conclusions/Significance: We show that a1A-AR-AB cause diastolic dysfunction independent of hypertension, and can
increase the sensitivity to Ang II. We suggest that a1A-AR-AB could contribute to cardiovascular endorgan damage.
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Introduction
a1-adrenergic receptors (a1-AR) mediate vascular smooth
muscle cell (VSMC) contraction, cardiac inotropy, hypertrophy,
and remodeling [1]. Others and we have described agonistic
autoantibodies against the a1-AR in hypertensive patients
[2,3,4,5]. We found earlier that a1-AR-autoantibody immunoad-
sorption reduced blood pressure in patients with refractory
hypertension [5]. In that study, rabbit or patient-derived a1A-
AR-autoantibodies were purified with chromatography and
characterized by epitope mapping and surface plasmon resonance
measurements. Phospholipase A2 group IIA (PLA2-IIA) and L-
type calcium channel (Cacna1c) genes were upregulated in
cardiomyocytes and VSMC after stimulation with both purified
antibodies from patients and from rabbit [5]. We showed that
patient and rabbit a1A-AR-antibodies result in protein kinase C
alpha activation and transient extracellular-related kinase (ERK1/
2) phosphorylation. The antibodies also exerted acute effects on
intracellular Ca
2+ in cardiomyocytes and contracted mesentery
artery segments [5]. In a proof-of-concept study involving the b1-
AR, Jahns et al immunized rats and showed that agonistic
autoantibodies caused idiopathic dilated cardiomyopathy in the
same rats. Furthermore, passive transfer also caused disease
[6].
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signaling, namely a1A-, a1B-, and a1D-AR. All subtypes were
expressed in cardiac tissue but differ in the amino acid sequence of
the second extracellular loop. Zhou et al immunized rats with a
second extracellular loop peptide from the a1D-AR subtype
epitope [7]. The rats developed agonistic antibodies. Tail-cuff
systolic blood pressure was not changed. The investigators
described cardiac hypertrophy, increase in the collagen deposition,
c-jun, and matrix metalloproteinase 2 (MMP2) expressions in the
heart. We immunized our animals against the second extracellular
loop of a1A-AR. This report is the first showing the in vivo
relevance of a1A-AR-AB (as opposed to a1D-AR-AB) to our
knowledge. We investigated the effects on blood pressure by
radiotelemetry and on cardiac function by invasive hemodynamic
measurements with a conductance catheter and echocardiogra-
phy. Cardiac molecular pathways influenced by a1A-AR-AB
signaling were investigated by gene expression array analyses.
Furthermore, we tested the hypothesis whether immunized rats
react more sensitive to angiotensin (Ang) II.
Materials and Methods
Immunization
Experiments were performed in 36 male Lewis rats aged 8
weeks. We prepared a synthetic GWRQPAPEDETICQINEEP-
GYVLFSAL-AmidxTFA/salt (Biosyntan GmbH, Berlin, Ger-
many) peptide corresponding to the second extracellular loop of
human a1A-AR. Eighteen rats were immunized by subcutaneous
injection (200 mg, treated with 350 mg methylated albumin)
dissolved in 1 mL saline at 0, 2, and 4 weeks. The animals were
boosted monthly over 12 months. Eighteen control rats received
saline. For Ang II infusion, osmotic pumps (Alzet, Cupertino, CA,
USA) were implanted under isoflurane anesthesia in the animals
(n=6 per group) 12 months after first immunization. The animals
received 200 ng Ang II/kg/min for 14 days (Calbiochem, La Jolla,
CA, USA). Local authorities (LAGeSO, Berlin, Germany)
approved the animal protocol that complied with criteria outlined
by the American Physiological Society.
a1-AR-AB Detection
Rat a1A-AR-AB were detected by peptide ELISA (CellTrend,
Luckenwalde, Germany). Rat sera (100 mL), 3 or 12 months after
first immunization, were added (dilution 1:1000). As second
antibody, we used rabbit anti rat IgG fc horseradish peroxidase
(HRP) conjugated (1:35000 diluted, 100 mL/well, Bethyl, Mon-
tgomery, TX, USA). The reaction was detected by tetramethyl-
benzidine (TMB) as substrate for the enzyme HRP.
Neonatal rat cardiomyocyte contraction assay and the detection
of extracellular regulated kinase 1/2 (ERK1/2) phosphorylation in
CHO cells stably transfected with human a1A-AR (CHO/a1A-AR)
were carried out as earlier described [5]. For the ERK1/2
phosphorylation experiments, 50 mg of IgG purified from sera of
rats 3 months after immunization and controls were added to the
CHO/a1A-AR cells for 10 min. We checked specificity by
inhibiting with 1 mMo fa1-AR antagonists prazosin or urapidil.
The development of AT1-AR-AB, b1-AR-AB, or b2 AR-AB
during immunization or Ang II treatment was excluded by
cardiomyocyte contraction assay in presence of the antagonists.
Echocardiography, Blood Pressure and Hemodynamic
Measurements
Rats were anesthetized with 2% isoflurane and kept warm on a
heated platform. Temperature and ECG were continuously
monitored. Cardiac function and morphology were assessed by
echocardiography with a VisualSonics Vevo 770 High-Resolution
Imaging System with the use of a high-resolution (37.5 MHz)
transducer. The telemetry system (Dataquest ART 4.0
TM, Data
Sciences International, St. Paul, MN, USA) and the implantation
procedure is described in detail by Brockway et al. [8]. The
radiotelemetry pressure transducers (TA11PA-C20) were implant-
ed in the abdominal cavity of the rat under isoflurane anesthesia,
with the transducer connected capillary tubing anchored in the
lumen of the abdominal aorta. Before the implantation the zero
offset was measured and the unit was soaked in 0.9% NaCl.
Animals were allowed to recover for 10 days. The data from the
TA11PA-C20 device were transmitted via radiofrequency signals
to a receiver below the home cage and thereafter collected
(sampling rate 500 Hz). The system monitors mean, systolic and
diastolic blood pressure, heart and respiration rate and locomotor
activity at 5-min intervals, while the rats move freely. We report
mean arterial blood pressure (MAP). For hemodynamic measure-
ments, rats were intubated and ventilated under isoflurane
anesthesia. A 2-French conductance catheter (SPR 838 Aria,
Millar Instruments, Houston, TX, USA) was inserted into the left
ventricle through the right carotid artery. The stroke volume (SV),
end-diastolic volume (Vol max), end-systolic volume (Vol min),
and LV-pressures were measured directly in acute experiments.
Gene Expression and Immunohistochemistry
Total RNA was extracted from the cardiac apex (one-third from
the whole heart including parts of left, right ventricle and septum) of
three immunized and three control rats using the RNeasy
Purification Kit (Qiagen GmbH, Hilden, Germany). RNA was
treated by deoxyribonuclease I (Qiagen). Two mg RNA of cells were
transcribed in cRNA with One-Cycle Target labeling and Control
Reagents (Affymetrix, Santa Clara, CA, USA). Non-pooled
microarray experiments were performed using Rat Genome 230
2.0 Arrays (31,099 probe sets, Affymetrix). Gene expression and
RT-PCR experiments were carried as previously described.[5]
Primer sequences for TaqMan analyses are listed in Supplementary
table S1. The MIAME-compliant microarray data are available
http://www.ebi.ac.uk/arrayexpress/experiments/E-TABM-725.
Cardiac tissues werefixed inparaformaldehydeand embedded in
paraffin. The 5 mm thick sections were deparaffinized, rehydrated,
and stained by the Trichrome-Masson-Goldner or 0.1% Sirius red
saturated in picric acid. Histomorphological analysis and cardio-
myocyte diameter was determined on elastica van Gieson and
hematoxylin-and-eosin–stained, 4 mm-thick sections of tissue placed
in 5% formalin. Cardiomyocyte diameter was determined perpen-
dicular to the outer contour of the cell membrane at the nucleus
level in 15 representative myocytes of the section as desribed by van
Heerebeek et al [9]. Heart sections were photographed at a
magnification of 10x (interstitial) or 20x (perivascular) with a Sony
AVT-Horn camera using Zeiss-Axioplan 2 microscope. 25
microscopic view fields (left ventricle and septum) were evaluated.
Perivascular fibrosis was analysed from cross sections of coronary
arteries (12 arteries per section). Analysis and quantification of
interstitial and perivascular fibrosis content were performed with
‘‘Image J’’ software public domaine (Wayne Rasband, NIH, USA).
Data are presented as fractional area of fibrosis content in % of
myocardial tissue. The investigators performing the analysis were
not aware of the experimental groups.
Statistics
For analysis of echocardiography, telemetric, and hemodynamic
measurements Mann-Whitney-test was used at P,0.05. Data are
expressed as mean 6 SD. Continuous variables (blood pressure
a1A-AR Antibodies
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variance with appropriate corrections.
Results
Immunization and a1A-AR-AB Detection
The cardiomyocyte contraction assay documented an increase
of a1A-AR-AB activity one month after first peptide injection
persisting over the immunization process of 12 months. Urapidil
inhibited the activity (Figure 1A). IgG fractions eluted from sera of
control rats were negative in the cardiomyocyte contraction assay
(Figure 1B). The development of autoantibodies against other
receptors during immunization or Ang II treatment was excluded
by cardiomyocyte contraction assay in presence of the specific
antagonists. The combination of a1A-AR-AB and Ang II increased
the cardiomyocyte contraction, compared to the effect of a1A-AR-
AB or Ang II alone (Figure 1C). A high titer of a1A-AR-AB was
detected by ELISA in the immunized rats. The controls did not
show a signal (Figure 1D). The incubation of CHO/a1A-AR cells
with IgG prepared from immunized rats resulted in a stronger
ERK1/2 phosphorylation than IgG fractions eluted from sera of
control rats (Figure 2A). The specificity was proven by inhibition
with the a1-AR receptor antagonist prazosin (62% inhibition,
P=0.023, Figure 2B).
Cardiac Function in Immunized Rats
The diastolic interventricular septum and diastolic left ventric-
ular heart wall thickness were significantly increased in 12 months
immunized rats compared to the controls (Figure 3 A). The ratio of
heart/body weight (HW/BW61000) was significantly increased in
the immunized rats compared to the controls (2.2160.23 vs.
1.9760.04, P=0.0471, Supplementary table S2). Fractional
shortening was similar in both groups, so that systolic function
was preserved (Figure 3 B). A decreased ratio of peak flow velocity
of the early rapid diastolic filling wave to peak flow velocity of the
late diastolic filling wave (E/A ratio) in immunized rats indicates
diastolic dysfunction (Figure 3 C). The echocardiographic findings
in vivo are summarized in Supplementary table S3. Hemody-
namic measurements showed higher left ventricular end-diastolic
pressures (LVEDP) in immunized rat hearts (Figure 3 D). No
changes in dp/dtmax confirmed the preserved contractility/systolic
function (Figure 3 E) and the decreased dp/dtmin indicates an
impaired relaxation/diastolic function (Figure 3 F). The analysis of
the mean cardiomyocyte diameters showed a significant hyper-
trophy 12 months after immunization with a1A-AR peptide,
compared to controls (Figure 3 G). The blood pressure (MAP) and
heart rate measured by telemetry were not different 12 months
after first immunization (Figure 4).
Gene Expression Analysis and Histology
Genes coding for proteins of the sarcomere and extracellular
matrix were differentially expressed in the heart (Table 1). Thus,
the myosin heavy chain alpha (a-MHC) and the myosin heavy
chain beta (b-MHC) were upregulated. Further, the collagen type I
maintaining tissue structure and collagen type IV, a component of
basal lamina that allows interaction with integrins and favors cell
Figure 1. Rat a1A-AR-AB detection. (A and B) Ordinate shows neonatal rat cardiomyocyte spontaneous beating rate; abscissa shows the
immunization time point. IgGs from immunized rats increased the beating rate (A), compared to controls (B) Specificity was checked by inhibition
with 1 mM urapidil (Urap). (C) We excluded autoantibodies against other receptors using the b1-AR antagonist propranolol (Prop) and the AT1
receptor antagonist irbersartan (Irb). The combination of a1A-AR-AB and Ang II increased the cardiomyocyte contraction. (D) A high titer of a1A-AR-AB
was detected by ELISA in immunized rats, compared to controls.
doi:10.1371/journal.pone.0009409.g001
a1A-AR Antibodies
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glycoprotein laminin was also upregulated. Other genes coding for
proteins involved in the Ca
2+ signaling were represented. Among
them were the cardiac ryanodine receptor 2 (Ryr2), the cardiac
ATPase 2 Ca
2+-transporting, slow-twitch (Atp2a2), and the L-type
calcium channel (Cacna1c). Important components of the energy
metabolism like muscle glycogen phosphorylase and the peroxi-
some proliferators-activated receptor-gamma, co-activator 1,
alpha (Ppargc1a) a master regulator of metabolic function
responsible for fatty acid uptake and oxidation and oxidative
phosphorylation[10] were upregulated (Table 1).
The gene expression results were validated by TaqMan analysis
for a-MHC (Fold change (FC)=3.5), b-MHC (FC=2.8), collagen,
type I, alpha 1 (FC=1.7), and Cacna1c (FC=2.0). The cardiac
expression of a1A-, a1B-o ra1D-AR subtype was not differential in
immunized and control rats one year after immunization. Sirius
red and Trichrome-Masson-Goldner staining were used for
fibrosis detection. More fibrosis occurred in immunized rats
Figure 2. ERK1/2 activation in CHO/a1A-AR cells. (A) Activation after incubation with IgG from immunized and control rats or with
phenylephrine (10 mM) for 10 min is shown. Lane 1 and 2 represent untreated cells. (B) The specificity of ERK1/2 activation by a1A-AR-AB was checked
by prazosin inhibition (Prz, 1 mM). Lane 1 represents untreated cells. Eukaryotic initiation factor 4E (elF4E) and ERK1/2 antibody were used as loading
control.
doi:10.1371/journal.pone.0009409.g002
Figure 3. Echocardiography and invasive hemodynamic by conductance catheter at 12 months after first immunization. (A)
Increased interventricular septum (IVS) and left ventricular heart wall (LVHW) thickness indicates hypertrophy. (B) Unchanged fractional shortening
was a sign for preserved systolic function. (C) A decreased E/A ratio in immunized rats indicated a diastolic dysfunction. (D) Immunized rats had
increased left ventricular end-diastolic pressure (LVEDP), (E) Unchanged dp/dtmax and (F) diminished dp/dtmin, indicating impaired relaxation/
diastolic function. (G) Mean diameter of cardiomyocytes showed a significant hypertrophy, 12 months after immunization with a1A-AR peptide
compared to controls. * indicates P,0.05, ** indicate P,0.01, *** indicate P,0.001.
doi:10.1371/journal.pone.0009409.g003
a1A-AR Antibodies
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significantly increased by a1A-AR-AB, whereas interstitial fibrosis
was significantly induced in combination with Ang II infusion
(Figure 6).
Ang II Effects in Immunized and Control Rats
We tested whether or not immunized rats react more strongly to
Ang II. Ang II further increased the chronotropic response of a1A-
AR-AB, whereas phenylephrine did not result in an incremental
increase in the bioassay (Supplementary figure S1). The
combination of a1A-AR-AB and Ang II caused a stronger increase
in MAP in immunized rats, compared to the Ang II treated
controls (Figure 4, P=0.0339). The ratio of heart/body weight
(HW/BW61000) was significantly increased in the immunized
rats compared to the controls (2.3160.13 vs. 2.0860.12,
P=0.0109, Supplementary table S2). We used Trichrome-
Masson-Goldner staining to quantify our results and found that
immunized rats developed more severe fibrosis than control rats
(Figure 5 A, B). The extent of fibrosis as a percent of tissue area
was significant higher in the immunized rats (14.464.54% vs.
8.9062.31% in controls, P,0.00001). Ang II also induced a
significant myocyte hypertrophy, which was not potentiated by
a1A-AR-AB (data not shown).
Discussion
The important findings in our study were that active
immunization results in production of activating antibodies to
the a1A-AR, namely a1A-AR-AB. The a1A-AR-AB in our model
did not increase telemetrically measured blood pressure. However,
they clearly caused cardiac target organ damage and resulted in a
model of diastolic dysfunction. Finally, stimulation of the system
with an additional stressor (Ang II) resulted in worsened target-
organ damage in the a1A-AR-AB-producing animals compared to
controls. The immediate question is, ‘‘how do the results reported
here differ from those of Zhou et al [7]?’’ We relied on a different
immunization sequence; our sequence corresponded to a1A-AR,
while Zhou et al used a sequence corresponding to a1D-AR. These
receptors are different. We investigated Ang II provocations, while
they did not. We focused on target-organ damage. Finally, we
monitored endorgan damage with echocardiography, invasive
hemodynamics, histological analysis, radiotelemetrically deter-
mined blood pressure measurements, and by gene expression
array.
The immunized rats developed specific a1A-AR-AB that we
detected by both cardiomyocyte contraction assay and ELISA.
The blocking experiments underscored the specificity of these
antibodies. The antibodies were capable of initiating a1A-AR
signaling as documented by our phospho-ERK1/2 experiments.
We documented clear-cut differences in cardiac function by two
independent techniques, one relying on direct cardiac catheteri-
zation that revealed a diastolic pathology. Cardiac structure was
substantially different between the groups, as shown by echocar-
diography and by light microscopy. Our notion that a much more
sensitive blood pressure measurement than the tail-cuff technique
would show a difference in blood pressure between groups, proved
Figure 4. Mean arterial blood pressure (MAP) and heart rate 12 months after first immunization, pre and post angiotensin (Ang) II
treatment. a1A-AR-AB in combination with the stressor Ang II cause a greater increase in blood pressure (A) and heart rate (B) in the immunized rats
compared to the Ang II-treated controls. * indicates P,0.05, ** indicate P,0.01.
doi:10.1371/journal.pone.0009409.g004
Table 1. Selected differentially expressed genes in hearts of
immunized rats.
Gene Ref.-Sequence Fold
change
Sarcomere
Myosin heavy chain, alpha NM_017239 2.7
Myosin heavy chain, beta NM_017240 2.3
Collagens and extracellular matrix proteins
Collagen, type I, alpha 1 NM_053304 1.5
Collagen, type I, alpha 2 NM_053356 1.6
Procollagen, type IV, alpha 1 XM_001067473 1.7
Procollagen, type IV, alpha 2 XM_001076134 1.5
Laminin, gamma 1 XM_001071300 1.9
Ca
2+-regulation
Ryanodine receptor 2, cardiac XR_006681 1.7
ATPase, Ca
2+-transporting, cardiac muscle, slow
twitch 2
NM_001110139 1.5
Ca
2+-channel, voltage-dependent, L type, alpha 1C NM_012517 1.5
Energy metabolism
Peroxisome proliferators-activated receptor-gamma,
coactivator 1, alpha
NM_031347 1.8
Muscle glycogen phosphorylase NM_012638 1.7
Phosphofructokinase, muscle NM_031715 1.5
doi:10.1371/journal.pone.0009409.t001
a1A-AR Antibodies
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clearly that when a driving force for hypertension is applied, the
presence of a1A-AR-AB clearly aggravates target organ damage
and blood pressure. Finally, we explored new mechanistic
pathways.
Our gene expression analyses showed different compensatory
mechanisms in structure and metabolism to maintain the cardiac
function. In contrast to the failing rat heart with a shift in myosin
isoform from a to b-MHC [11], we found instead an increased
expression of both MHC isoforms. Up-regulation of b-MHC
transcription can serve as an early and sensitive marker of cardiac
hypertrophy [11,12] and may conserve energy [13,14]. Forced
expression of a-MHC may be beneficial in terms of increasing the
myocardial contractility and may result in cardioprotection
[15,16].
Myocardial remodeling implies an alteration in the extracellular
matrix composition and distribution. Accordingly, we found in our
array analysis the upregulation of collagen type I and IV in
immunized rat hearts. Collagen I and III maintain the tissue
structure, transmit forces throughout the myocardium and
contribute to the elastic properties of the myocardium [17]. The
increased accumulation of collagen I and III has been associated
mostly with fibrosis [18,19]. Type IV and VI collagens are
components of the basal lamina and favors cell adhesion. The
increased expression could be involved in the alteration of
extracellular matrix cell interaction [20]. In human dilated
cardiomyopathy, collagen is degraded by metalloproteinases and
is replaced by fibrous intercellular deposits [21]. Zhou et al found
increased MMP2 expression and activity in their a1D-AR-AB
immunization study [7]. We did not observe any increased
metalloproteinase or tissue inhibitors of metalloproteinases. Other
up-regulated genes encode molecular regulators of energy
metabolism. The peroxisome proliferator-activated receptor
gamma (PPAR-c) coactivator 1-alpha (Ppargc1a) activates multiple
genes that are responsible for fatty acid uptake and oxidation and
for oxidative phosphorylation [10]. The development of heart
failure is accelerated by Ppargc1a deficiency [22], suggesting that
this coactivator may have a cardioprotective function.
Another important observation is the fact that genes coding for
important Ca
2+ regulating proteins, such as ATPase, Ca
2+
transporting, slow-twitch (Atp2a2) coding for the sarcoplasmic/
endoplasmic reticulum calcium ATPase (SERCA2a), the cardiac
ryanodine receptor 2, and the L-type calcium channel, alpha 1 C
subunit (Cacnac1c) were all up-regulated. The overexpression of
SERCA2a in diseased hearts has been shown to result in the
recovery of contractility [23,24,25] and in improved survival,
corresponding with an improvement in energy consumption [26].
Furthermore, SERCA overexpression decreases or prevents
cardiac hypertrophy [27,28,29]. In our earlier study we found
that acute administration of purified a1-AR-autoantibodies from
patients or rabbit a1A-AR-AB to neonatal cardiomyocytes affected
intracellular Ca
2+ at two different levels, namely the acute, short-
term elevation of intracellular Ca
2+, and the increased transcript
expression of Cacna1c [5]. In this study, we also found a long-term
upregulation of Cacna1c. A link between increased L-type calcium
channel, alpha 1 C subunit levels and hypertrophy has also been
demonstrated for the human heart [30].
Rysa et al. performed DNA microarray analysis in 12 month-
old SHR with manifest hypertrophy, compared to 16–20 month-
old SHR with diastolic dysfunction and transition to heart failure
[31]. Most of the enhanced genes upregulated in the development
of diastolic heart failure encoded for ECM proteins. ECM proteins
were also upregulated in our study. However, whereas we found
dysregulated transcripts for calcium homeostasis, myofilament
contractile proteins, and cardiomyocyte cytoskeleton proteins,
these pathways seemed not to play a significant role in the
development of diastolic heart failure caused by pressure-overload
hypertrophy. The two models and the experimental settings were
considerably different. Our a1A-AR-immunized rats were only 12
months old, had no hypertension, and no signs of heart failure,
whereas the SHR rats were older and had signs of pressure-
induced diastolic heart failure. Interestingly, Wallukat et al have
shown that SHR develop autoantibodies against the b1 adrenergic
receptor that permanently stimulate the receptor, while a1-AR-AB
have not been found [32,33].
The a1-adrenergic receptors are important to both developmen-
tal cardiomyocyte growth and pathological hypertrophy. The a1A-
AR-AB production induced hypertrophy by causing fibrosis and
cardiomyocyte hypertrophy. Patel et al [34] showed that a 28-day
infusion of a subpressor norepinephrine dose induced hypertrophy
only by stimulating myocyte growth. No fibrosis or signs of diastolic
dysfunction was present in their 28-day study. However, we
Figure 5. Cardiac remodeling and fibrosis in immunized rats,
pre and post Ang II treatment. (A) Sirius red and (B) Trichrome-
Masson-Goldner staining. Both stains showed marked fibrosis in the
hearts of immunized rats. a1A-AR-AB, in combination with the stressor
Ang II cause a significantly higher increase of fibrosis in immunized rat
hearts compared to the Ang II treated controls (Bar=0.2 mm).
doi:10.1371/journal.pone.0009409.g005
a1A-AR Antibodies
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animals transgenic for the a1A-AR showed a greater increase in
myocardial fibrosis post-myocardial infarction, compared to the
non-transgenic control animals. Transgenic lines with an even
higher expression level developed progressive cardiac fibrosis.
In spite of subtype-selective agonists and antagonists and gene
knockoutandtransgenicoverexpressionapproaches, the question of
which a1-AR subtype is involved predominantly in vasoconstrictive
responses to sympathomimetic agonists has not been answered. The
studies with knockout mice indicate that all subtypes play a role in
the blood pressure response to a1-agonists and that the dominant
contractile a1-AR is different in different vascular beds. Although
we did not observe an increase in blood pressure by a1A-AR-AB,
our results do not justify the conclusion that the a1A-AR is not
involved in the blood pressure control. Our results are in line with
results reported by Tanoue et al [36]. These investigators found a
major role for a1A-AR in maintaining basal blood pressure, whereas
other subtypes such asa1B-AR and a1D-ARweremore important in
the pressor response to catecholamines.
Our immunized a1-AR-AB-producing rats developed an
increased LVEDP and diminished dp/dtmin in the face of
preserved ejection fraction and fractional shortening. This state-
of-affairs is termed ‘‘diastolic dysfunction’’ and is a precursor for
diastolic heart failure. Half the patients with heart failure fall into
this category, notably older women. The prognosis of the
condition is no better, if not worse, than systolic heart failure.
All medication trials to date have been disappointing. The a1-AR
blockers have not been studied in detail in the context of diastolic
dysfunction. Two smaller studies reported positive effects of a1-AR
blockers on echocardiographic parameters of diastolic dysfunction.
To our knowledge, this experimental model is the first to show that
a1A-AR receptor stimulation can cause diastolic dysfunction
independent of any change in blood pressure. De Blois et al
showed that chronic a1-AR stimulation increases smooth muscle
cell DNA replication is in arterial wall, leading to remodeling after
vascular injury [37]. We speculate that alterations in peripheral
resistance (pressure-overload) could have been responsible for the
diastolic dysfunction we observed. The fact that we were unable to
detect any blood pressure increases even with radiotelemetry,
suggests the possibility that altered blood pressure buffering played
a role. We demonstrated heart muscle cell (cardiomyocyte)
hypertrophy, in addition to an increased cardiac fibrosis in the
a1A-AR-AB model. We believe that these changes, independent of
any blood pressure changes we were able to detect, resulted in the
diastolic dysfunction that we observed.
Our Ang II experiments showed that Ang II markedly
aggravated the already-present cardiac fibrosis. We used Ang II
as a stimulus to further induce vascular dysfunction. The
sympathetic nervous system and renin-angiotensin-aldosterone
system act synergistically to elevate or maintain blood pressure.
Ang II signaling plays a critical role in modulating many of the
stimuli and signals that govern arterial aging, arterial structural,
and vascular functional and adaptational responses. Ang II also
potentiated the chronotropic response to a1A-AR-AB, whereas
phenylephrine infusion, as reported by Patel et al, did not [22].
Limitations in our study are the fact that we did not include a
long-term treated control group, namely immunized rats produc-
ing a1A-AR-AB treated with chronic a1-AR blocker therapy. An
additional desirable control group could consist of chronic
phenylephrine infusion (for 1 year). Acute infusion experiments
could elucidate the issue of baroreceptor reflex blood pressure
buffering capacity or resetting that remains unanswered from our
study. However, our acute experiments showed that the effects of
a1A-AR-AB could be blocked pharmacologically. Chronic exper-
iments could have allowed us to speculate with greater confidence
on a possible role of a1-AR blockade to alleviate diastolic heart
dysfunction and remodeling.
Perspectives
We elucidated agonistic autoimmunity-induced target-organ
damage and showed that a1A-AR-AB after immunization caused
diastolic dysfunction. Our animal model suggests that a1A-AR-AB
could play a role in target-organ damage; however a1A-AR-AB are
probably not initiators of hypertension. These findings have
implications for the notion of viewing agonistic autoantibodies as
primary treatment targets in human diseases [38]. Our findings
also have implications concerning a1-AR blocker therapy. These
agents may warrant a closer look, particularly in terms of diastolic
dysfunction.
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cardiomyocytes with I ˆ61A-AR-antibodies (AB) or phenylephrine
Figure 6. Myocardial perivascular and interstitial collagen. (A) Perivascular fibrosis was significantly increased in all three treated groups
compared to control rats. (B) Interstitial fibrosis was significantly increased in immunized rats treated with Ang II when compared to controls, rats
treated with Ang II or immunized rats.
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